Europe Gout Therapeutics Market is segmented By Pet Type (Dog, Cat), By Ingredient (Prebiotics and Probiotics, Enzymes, Omega-3 and Omega-6 Fatty Acids, Vitamins and Minerals, Others), By Form (Dry Food, Wet Food, Freeze-Dried Food, Others), By Application (Joint Health, Weight Management, Skin and Coat, Dental Health, Digestive Health, Others (Immunity, Mental Acuity, Calming)), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Growing adoption of biologics and increasing R&D on regenerative medicines
The major factors driving the growth of the market are rising adoption of biologics and increasing R&D on regenerative medicines, technological advancements in imaging modalities improved. This condition can be treated or prevented with the use of drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents.
Biologics have witnessed rapid adoption and are replacing NSAIDS and corticosteroids owing to better results. Hence, the biologics segment is anticipated to expand at a rapid pace and is likely to gain gout therapeutics which drive the market growth in the forecast period.
Increasing product approvals by regulatory authorities is expected to drive growth of the gout disease treatment market. Manufacturers are adopting acquisition & collaboration and new product development strategies to tap the unmet needs of a large proportion of patient pool. For instance, AstraZeneca announced that the European Commission (EC) has granted marketing authorization for ZurampicTM(lesinurad) 200mg in combination with a xanthine oxidase inhibitor (XOI) for the adjunctive treatment of hyperuricemia in adult gout patients (with or without tophi) who have not achieved target serum uric acid (sUA) levels with an adequate dose of an XOI alone.
Increasing pipeline drugs for the treatment of gout by several major companies is also expected to boost the market growth of the forecast period. For instance, in December 2021, Alnylam Pharmaceuticals, Inc., a RNAi therapeutics company, has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a Phase 1/2 study of ALN-XDH, an investigational RNAi therapeutic targeting xanthine dehydrogenase (XDH) for the treatment of gout.
Europe Gout Therapeutics Market Scope
|
Metrics |
Details |
|
Market CAGR |
5% |
|
Segments Covered |
By Pet Type, By Ingredient, By Form, By Application, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
Growing burden of gout therapeutics with the increasing geriatric population
The major factors that fuel the growth of the market are the growing burden of gout therapeutics with the increasing geriatric population. It usually affects the geriatric population, and the prevalence is seen higher in females as compared to males. Therefore, larger cases of this disease can be found in aged population reaching hospitals. A retrospective analysis of patients with gout, identified through the records of 2.5 million patients in UK. The prevalence of gout was 1.4% in the UK and Germany. Obesity was the most common comorbidity in the UK (27.7%), but in Germany the most common comorbidity was diabetes (25.9%).
Gout prevalence in the adult population of France in 2013 was estimated at 0.9%. Studies using self-reporting only might overestimate the prevalence. Numerous epidemiologic studies have shown that gout is the most common inflammatory arthritis in men in France among men ages 35–39 years and 2.0% among men 40–44 years. Gout therefore appears to be the most frequent inflammatory arthritis in French adults, with a prevalence approximately 3-fold higher than that for rheumatoid arthritis.
The gout therapeutics market in the France is likely to expand at a rapid pace during the forecast period. The country is projected to retain its share of the gout therapeutics market from 2019 to 2027. Moreover, high incidence of gout arthritis is anticipated to propel the market in the France during the forecast period.
Side-effects of gout therapeutic drugs
Factors such as the adverse effects of the drugs may hamper the market growth. In Europe there have been reports of patients dying of renal failure after using benzbromarone, because of the side effects, doctors tend to prescribe low-dose colchicine for people with renal or hepatic impairment. People with renal or hepatic impairment and those who also take other drugs for chronic diseases could experience serious side effects from colchicine. In addition, corticosteroids, such as prednisone, can be prescribed to reduce pain and inflammation. They can increase blood sugar levels and blood pressure and may induce mood changes. Side effects can include nausea, diarrhea and vomiting.
DataM Analysis Report
The Europe gout therapeutics market is expected to expand at a sluggish CAGR of 7% during the forecast period (2022-2029). Demand for effective therapeutics for gout treatment is increasing. Numerous pipeline products and recent approvals of drugs to treat gout therapeutics are expected to the new opportunity for the market. New medication are being developed, such as arhalofenate, which is estimated to target renal transporters of uric acid, primarily URAT1 and OAT4, acting as uricosuric agents. Arhalofenate has been investigated for the treatment of Gout and Hyperuricemia.
Market Overview
- According to DataM Intelligence latest research report on the gout therapeutics market in Europe for the historical period 2020 & 2021 and the forecast period 2022–2029.
- In terms of revenue, the gout therapeutics market in the Europe is estimated to surpass US$ 5,902.4 Mn by 2027, expanding at a CAGR of 7% throughout the forecast period.
Key Drivers
The Europe gout therapeutics market is impacted by several factors such as rising prevalence of gout in this region due to change in lifestyle, increasing alcohol consumption, increasing obesity & kidney diseases, high purine diet, and consumption of several medications such as diuretics. Other major factors driving the growth of the market are rising adoption of biologics and increasing R&D on regenerative medicines, technological advancements in imaging modalities improved. This condition can be treated or prevented with the use of drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents.
Growing demand for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
The non-steroidal anti-inflammatory drugs (NSAIDs) are estimated to dominate the gout therapeutics market in 2020, owing to availability of these drugs at a lower cost compared to other drugs, high level of penetration of drugs, and the ability to relieve pain in case of an acute gout attack. NSAIDs are the first line drugs used to decrease the inflammation and the associated pain of rheumatic and non-rheumatic diseases.
Competition Landscape
- Detailed profiles of providers of gout therapeutics have been provided in the report to evaluate their financials, key product offerings, recent developments, and strategies
- Some of the major players of the market are Novartis AG, Merck & Co. Inc., Teva Pharmaceuticals Industries Limited, Boehringer Ingelheim Group, Astrazeneca Plc, Takeda Pharmaceutical Company, CymaBay Therapeutics, Inc., JW Pharmaceutical Corporation, Romeg Therapeutics, LLC, Avion Pharmaceuticals, LLC, among others.
Strategic Partnerships
- The Europe gout therapeutics market is highly competitive with the presence of major players and small emerging players. In the gout therapeutics market, the market players are involved in developing cost-effective drugs to gain market share. The market players are adopting various key strategies such collaborations, partnerships, acquisition, product launch to expand their presence. Some other key strategies in the Gout Therapeutics market in Europe are highlighted below:
- In May 2021, Fortress Biotech, Inc., an innovative biopharmaceutical company, has entered into an exclusive licensing agreement with Fuji Yakuhin Co. Ltd. to develop Dotinurad in the United States, United Kingdom, European Union and Canada. Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor that was approved for the treatment of gout and hyperuricemia in Japan in 2020.
- In the Europe gout therapeutics market report, we have discussed individual strategies, followed by company profiles of manufacturers of drugs used for treatment of gout. The ‘Competition Landscape’ section has been included in the report to provide readers with a dashboard view and company market share analysis of key players operating in Europe.
Frequently Asked Questions
What is the Projected CAGR value of the Europe Gout Therapeutics Market?
Europe Gout Therapeutics Market is expected to grow at a CAGR of 5% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Europe Gout Therapeutics Market during 2022-2029.
Which is the fastest growing region in the Europe Gout Therapeutics Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period.
